Positive changes in drug program for women with SMA
An important change introduced in the drug program B.102.FM. "Treatment of patients with spinal muscular atrophy," took effect on April 1, 2024, and applies to women with SMA who want to have offspring. The Ministry of Health has decided to continue nusinersen treatment during pregnancy. The changes introduced meet the existing needs of adult SMA patients, who previously had to discontinue treatment during pregnancy, which was associated with a worsening of their condition. The current decision will improve the quality of life of patients with spinal muscular atrophy who choose to become mothers.
- The drug has been registered very broadly from the beginning for the treatment of SMA regardless of the patient's age or the copy number of the SMN2 gene, which is the most important factor modifying the rate of disease progression. In terms of the drug's use in pregnant women, the drug's product characte...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
